Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)

Leukemia. 2016 Jul;30(7):1580-2. doi: 10.1038/leu.2015.340. Epub 2015 Dec 15.

¹ Department for Hematology, Oncology and Clinical Immunology, University Hospital, Heinrich-Heine-University, Duesseldorf, Germany.
² Department of Hematology, Oncology and Palliative Care, Marien Hospital Duesseldorf, Duesseldorf, Germany.
³ University Medicine Goettingen, Clinics of Hematology and Medical Oncology, Goettingen, Germany.
⁴ Hannover Medical School, Institute of Pathology, Hannover, Germany.
⁵ Department of Hematology, University Hospital Dresden, Dresden, Germany.
⁶ Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany.
⁷ Department of Internal Medicine, Technical University of Munich, Munich, Germany.
⁸ Department of Internal Medicine, University Hospital Ulm, Ulm, Germany.
⁹ Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
¹⁰ Department of Hematology and Oncology, Charité, Benjamin Franklin University, Berlin, Germany.
¹¹ University Hospital Freiburg, Internal Medicine, Freiburg, Germany.
¹² Department of Internal Medicine, University Hospital Frankfurt, Frankfurt, Germany.
¹³ Department of Oncology, Hematology, BMT with section Pneumology, Hubertus Wald Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

No abstract available

Publication types